Death receptors as targets in cancer - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Pré-Publication, Document De Travail Année : 2014

Death receptors as targets in cancer

Résumé

Anti-tumour therapies based on the use PARAs (pro-apoptotic receptor agonists), including TRAIL (TNF-Related Apoptosis inducing Ligand) or monoclonal antibodies targeting TRAIL-R1 or TRAIL-R2, have been disappointing so far, despite clear evidence of clinical activity and lack of adverse events for the vast majority of these compounds, whether combined or not with conventional or targeted anti-cancer therapies. This brief review aims at discussing the possible reasons for the lack of apparent success of these therapeutic approaches and at providing hints in order to rationally design optimal protocols based on our current understanding of TRAIL signalling regulation or resistance for future clinical trials.
Fichier principal
Vignette du fichier
Figures_Micheau.pdf (1.68 Mo) Télécharger le fichier
BJP_review_Micheau_2013.pdf (475.64 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

inserm-00823459 , version 1 (01-05-2014)

Identifiants

  • HAL Id : inserm-00823459 , version 1

Citer

Olivier Micheau, Sarah Shirley, Florent Dufour. Death receptors as targets in cancer. 2014. ⟨inserm-00823459⟩
734 Consultations
528 Téléchargements

Partager

Gmail Facebook X LinkedIn More